CMND Stock Set For Biggest Intraday Gains In Over Three Years — Here’s Why Retail Is Eyeing Further Upside

• Trump also allocated $50 million in federal funding for related research.
• Clearmind has a patent for a treatment that combines Ibogaine with N-Acylethanolamines.
• Meanwhile, investors are also tracking Silo Pharma, which is currently developing SPC-15, a nasal spray designed to help prevent post-traumatic stress disorder.

Shares of Clearmind Medicines (CMND) surged nearly 65% in pre-market trading on Monday, putting the stock on track for its biggest intraday gain since August 2022, after U.S. President Donald Trump signed an executive order to accelerate access to psychedelic-based treatments.

Separately, Clearmind Medicine, on Monday, said its drug CMND-100 met the main goal in an early-stage trial for Alcohol Use Disorder. The treatment showed strong safety, with no serious side effects reported, even at higher doses.

$50M PTSD Boost

On Saturday, Trump signed an executive order to accelerate research and access to psychedelic-based therapies, bringing renewed attention to treatments for post-traumatic stress disorder (PTSD). The order directs the U.S. Food and Drug Administration to fast-track the review of drugs such as Ibogaine, while allocating $50 million in federal funding for related research.

Ibogaine, derived from a Central and West African shrub, remains a Schedule I substance in the U.S., though interest is rising among veteran groups exploring its therapeutic potential. Officials say the move could pave the way for reclassification if clinical trials prove successful, with decisions potentially coming as early as this summer.

All Eyes On Clearmind’s Ibogaine Combination Therapy

Clearmind has a patent for a treatment that combines Ibogaine with N-Acylethanolamines, a type of fatty acid amide. The patent builds on Clearmind’s collaboration with SciSparc, in which both companies are developing combination therapies pairing psychedelic compounds with molecules such as Palmitoylethanolamide to improve treatment outcomes.

Ibogaine has shown promise in clinical studies for treating opioid, cocaine, and other substance use disorders, making it a potential anti-addiction therapy.

SILO stock was down 3% at the time of writing.

Silo’s SPC-15 Development Gets A Boost

Meanwhile, Silo Pharma (SILO) also generated a strong buzz after Trump’s order. The firm is currently developing SPC-15, a nasal spray designed to help prevent post-traumatic stress disorder. The treatment uses a fast nose-to-brain delivery approach. It is being developed under a faster regulatory pathway, the firm added.

“Momentum at the national level around psychedelic therapeutics reflects what the science has been signaling for years—there is a critical need for new approaches to treating mental health conditions. We believe Silo is well positioned with SPC-15 and its broader CNS pipeline to potentially benefit from a more favorable regulatory and clinical environment,” said Eric Weisblum, CEO of Silo Pharma.

How Did Retail Traders React?

Retail sentiment for CMND on Stocktwits turned ‘extremely bullish, while sentiment for SILO was ‘bullish.’ Message volumes for CMND were ‘extremely high,’ a whopping 535% increase over the past 24 hours, according to Stocktwits data.

One user tracking CMND saw the $1.35-$1.37 level as key resistance.

Another user highlighted CMND’s “good results,” adding that the stock could climb over $2.

Year-to-date, CMND shares have declined by more than 66%, while SILO stock has climbed by around 40%.

For updates and corrections, email newsroom[at]stocktwits[dot]com.